Loading...
•
May 31, 2022
Nurix Q2 2022 Earnings Report
Nurix reported second quarter 2022 financial results and provided a corporate update.
Key Takeaways
Nurix Therapeutics reported collaboration revenue of $11.4 million for the second quarter of 2022, compared to $7.1 million for the same period in 2021. The net loss for the quarter was $45.4 million, or ($1.01) per share, compared to a net loss of $26.4 million, or ($0.60) per share for the same period in 2021. The company's cash, cash equivalents, and investments totaled $348.8 million as of May 31, 2022.
NX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial
First patient dosed in NX-5948 Phase 1a clinical trial for certain B-cell malignancies
NX-1607 IND cleared FDA for expansion of enrollment to U.S. clinical sites for patients with solid tumors
Research engine achieved collaboration milestone for fifth consecutive quarter
Nurix
Nurix
Nurix Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Nurix anticipates a payment of $1.5 million in the third fiscal quarter of 2022 related to a research milestone achieved under its collaboration with Gilead.